Bookbuilding IPO | ₹[.] Cr | Listing at BSE, NSE |
SEBI has approved the Initial Public Offer (IPO) of Integris Medtech Ltd. on February 13, 2026. The company will proceed with next steps to launch the Initial Public Offer (IPO) subject to market conditions and other approvals. The SEBI approval is valid for 12 months.
Integris Medtech Ltd. IPO is a Book Build Issue consisting of fresh issue of ₹925.00 crores and an offer for sale (OFS) of upto 2.17 crore equity shares.
The equity shares are proposed to be listed on NSE and BSE. ICICI Securities Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue. Key details like IPO dates, IPO price bands and lot size are yet to be announced.
Refer to Integris Medtech IPO DRHP for more details.
| IPO Date | [.] |
| Listing Date | [.] |
| Face Value | ₹1 per share |
| Price Band | |
| Lot Size | |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Fresh Issue | [.] shares (agg. up to ₹925 Cr) |
| Offer for Sale | 2,16,74,531 shares of ₹1 (agg. up to ₹[.] Cr) |
| Share Holding Pre Issue | 10,83,38,049 shares |
| Description | Date |
|---|---|
| Filed with SEBI/Exchange | Thu, Oct 9, 2025 |
| SEBI/Exchange approval received | Fri, Feb 13, 2026 |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not less than 75% of the Offer |
| Retail Shares Offered | Not more than 10% of the Offer |
| NII Shares Offered | Not more than 15% of the Offer |
Incorporated in 2008, Integris Medtech Ltd is a diversified India-based global medical products and laboratory solutions company. The company develops, manufactures, commercialises, and sells a broad portfolio of medical devices and solutions spanning cardiovascular devices, clinical diagnostics, and scientific laboratory solutions.
Integris Medtech operates manufacturing facilities in India, Germany, and the Netherlands, supplying products to more than 65 international markets across India, Europe, and Southeast Asia. Its customer base includes over 9,500 laboratories and 2,000 hospitals and cathlabs, supported by a portfolio exceeding 22,000 SKUs across more than 200 brands in laboratory and cardiovascular segments.
The company’s business is structured into two core divisions:
Integris Medtech supports laboratories and hospitals across India, Singapore, Thailand, Malaysia, and the Philippines, serving both public and private sectors.
Its European operations focus primarily on cardiovascular products, including proprietary brands like Chrome and Protégé, while its Rest of World presence spans the Middle East, Africa, and Latin America.
As of June 30, 2025, Integris Medtech employed 1,879 personnel, including sales, service, and application specialists, and had supported more than 15,000 patients across 100+ clinical trial sites globally, reinforcing its commitment to clinical evidence and innovation in MedTech solutions.
Integris Medtech Ltd.'s revenue increased by 24% and profit after tax (PAT) rose by 1547% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 4,019.62 | 3,641.34 | 2,989.20 | 2,553.87 |
| Total Income | 508.93 | 1,959.58 | 1,582.26 | 1,369.66 |
| Profit After Tax | 267.57 | 70.68 | -4.88 | -40.54 |
| EBITDA | 78.73 | 309.40 | 190.45 | 168.82 |
| NET Worth | 3,889.99 | 2,752.52 | 2,681.02 | 2,629.52 |
| Reserves and Surplus | 2,299.84 | 1,150.74 | 1,135.71 | 1,073.12 |
| Total Borrowing | 793.42 | 1,729.46 | 813.10 | 556.54 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by: | 696.39 |
| 2 | The wholly-owned Subsidiaries, namely, Translumina Therapeutics Private Limited (“Translumina Therapeutics”), Transhealth Private Limited (“Transhealth”) ”) and HaleMed Medical Private Limited; and | 125.40 |
| 3 | The step-down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Supplies Inc., Hausen Bernstein Co. Ltd, Medigene Sdn. Bhd., Research Instruments Sdn Bhd and Research Instruments Pte. Ltd. | 571.00 |
| 4 | General corporate purposes |
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 5.35% |
| ROCE | 14.51% |
| RoNW | 1.48% |
| PAT Margin | 3.72% |
| EBITDA Margin | 16.26% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 6.52 | |
| Promoter Holding | 83.24% |
Lead Manager Reports
Integris Medtech IPO is a main-board IPO of 0 equity shares of the face value of ₹1 aggregating up to ₹[.] Crores. The issue is priced at To be declared. The minimum order quantity is .
The Integris Medtech IPO open and close dates are not available as of now.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Integris Medtech IPO using UPI as a payment gateway. Zerodha customers can apply in Integris Medtech IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Integris Medtech IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Integris Medtech IPO dates are not announced. Please check back again after some time.
Integris Medtech IPO lot size and the minimum order quantity is not available at this time. Please check again later.
You can apply in Integris Medtech IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Integris Medtech IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Integris Medtech IPO allotment status.
The Integris Medtech IPO listing date is not yet announced. The tentative date of listing is .
